• "Biotech where science and spirit meet..."
Skip to content

Cannabis Companies Eyeing How Plant Could Help Autism Symptoms

After seeing some success around a treatment for epilepsy, the cannabis industry is increasingly eyeing for products for people with the autism spectrum disorder. Autism is a lifelong developmental disorder that affects communication, behavior and the ability to socialize. As many as one in 54 children are currently diagnosed with autism, according to Centers for Disease Control, and so are millions of adults. In addition…

BrainStorm to study stem cell treatment in Alzheimer’s patients

TEL AVIV (Reuters) – BrainStorm Cell Therapeutics Inc said on Wednesday it will begin a clinical trial of its experimental stem cell treatment in patients with Alzheimer’s disease. The U.S.-Israeli company is already conducting advanced trials of its treatment called NurOwn in patients with the neurodegenerative disease amyotrophic lateral sclerosis (ALS). MORE…

BCLI: ALS ASSOCIATION AND I AM ALS AWARDS $500,000 GRANT; POTENTIAL INCLUSION IN RUSSELL 3000 INDEX…

$500,000 Grant from ALS Association and I AM ALS On June 9, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced a combined grant of $500,000 from the ALS Association and I AM ALS to support an ALS biomarker study utilizing samples and data from the ongoing Phase 3 clinical trial of NurOwn® in ALS patients. The goal of…

AstraZeneca approaches Gilead about merging

NEW YORK — AstraZeneca PLC has made a preliminary approach to rival drug maker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health care deal on record. The UK company informally contacted Gilead last month to gauge its interest in a possible tie-up,…

FDA hits Novartis with unexpected 3-month delay on MS drug ofatumumab

Last week, Novartis was touting positive data showing its repurposed leukemia drug ofatumumab outpaced Sanofi’s Aubagio in a multiple sclerosis trial. Now, Novartis has revealed that the FDA, which was supposed to hand down a verdict on the drug this month, needs until September to make the decision. What happened? Novartis isn’t saying much. MORE……

DIABETIC RETINOPATHY TREATMENT MARKET 2020 TO WITNESS REMARKABLE GROWTH | LEADING PLAYERS ARE SIRNAOMICS INC., AERPIO, ALLERGAN, SIRNAOMICS, INC., AMPIO PHARMACEUTICALS INC., GLYCADIA, INC.

The primary sources employed while generating this Diabetic Retinopathy Treatment Market report include the industry experts from the industry comprising the management corporation, processing organizations, analytical service suppliers of the industry’s value chain. All primary sources are interviewed to accumulate the data and validate qualitative & quantitative information and conclude future prospects. Secondary research consists…

Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)

Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achieved no evidence of disease activity (NEDA-3) within the first (0–12 months) and second year (12–24 months) of treatment, respectively1 Regulatory action for ofatumumab in RMS…

Gilead to donate 300,000 more remdesivir doses to US hospitals

Gilead will increase the number of doses of remdesivir it’s donating to the federal government in the next six weeks, STAT reported. The drugmaker had planned to donate 607,000 vials of remdesivir — the drug that received FDA emergency approval for use in treating COVID-19 patients after it was shown to shorten recovery time in patients with the virus…

NurOwn May Curb Damaging Brain Inflammation in ALS Patients, Study Suggests

NurOwn, a cell-based therapy that protects and helps repair nerve cells, also may be able to curb the damaging brain inflammation that contributes to the progression of amyotrophic lateral sclerosis (ALS), recent findings suggest. Researchers believe this newly-found potential may extend the benefits of NurOwn in ALS patients and possibly among those with other conditions….

BCLI: THE COUNTDOWN TO PHASE 3 ALS DATA BEGINS…

BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is currently conducting a Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS) (NCT03280056). A total of 200 patients were randomized 1:1 to receive NurOwn® or placebo in the randomized, double blind, placebo controlled, multi-dose trial. Cells were extracted once from each patient prior to treatment,…